UNICURE-HD:法国单次插入图像引导高剂量率近距离放疗治疗局部晚期宫颈癌的多中心回顾性队列研究
该多中心回顾性队列纳入363例局部晚期宫颈癌患者,评估单次插入图像引导自适应近距离放疗的可行性、早期疗效与毒性。中位随访20.2个月,3年局部控制率为83.1%,MRI引导计划者局部控制率高于CT-MRI融合计划者,≥3级毒性发生率为14.0%。
要点
- 单次插入高剂量率图像引导自适应近距离放疗在局部晚期宫颈癌中可行。
- 3年局部控制率83.1%,MRI引导计划者达93.5%。
- ≥3级毒性事件发生率为14.0%。
核心结论
- 在该多中心真实世界队列中,整体局部控制率较高,尤其是采用MRI引导、施源器在位计划的患者。
- 单次插入高剂量率图像引导自适应近距离放疗治疗局部晚期宫颈癌可行,副作用方面与历史多插入系列大致一致。
研究设计与样本
- 法国多中心回顾性队列研究,纳入363例连续患者(FIGO 2009 IB-IVA期)。
- 患者接受同步放化疗(盆腔±腹主动脉旁IMRT/VMAT,45 Gy/25次,必要时受累淋巴结加量),随后1次施源器插入给予4次高剂量率近距离放疗。
- 计划以MRI引导(施源器在位)为主,否则采用CT引导并 rigid fusion 至数天前MRI。
- 复合剂量按线性二次模型转换为2 Gy分次等效剂量。
- 从放疗结束起用Kaplan-Meier法估算局部控制、淋巴结和远处控制、总生存和无病生存。
主要发现
- T2b为最常见T分期(59.5%),47.9%患者有淋巴结受累。
- 中位总治疗时间(OTT)为56天(IQR 50-61)。
- D90-CTVHR中位值为85.9 GyEQD2(IQR 80.4-91.6 GyEQD2)。
- 中位随访20.2个月(范围1.6-121个月),Kaplan-Meier估算3年局部控制率为83.1%(95% CI 76.4-88.0)。
- 未调整Kaplan-Meier显示,36个月时MRI为中心计划者局部控制率高于CT-MRI融合计划者(93.5% [85.7-97.2] vs 78.5% [70.4-84.6])。
关键数值与推荐
- FIGO 2009 IB-IVA期局部晚期宫颈癌。
- 同步放化疗:盆腔±腹主动脉旁IMRT/VMAT 45 Gy/25次,必要时受累淋巴结加量。
- 近距离放疗:1次施源器插入,给予4次高剂量率分次。
- 计划MRI引导(施源器在位)或CT引导 rigid fusion 至数天前MRI。
- 复合剂量按线性二次模型转换为2 Gy分次等效剂量。
临床怎么用
- 在近距离放疗资源有限地区,单次插入高剂量率图像引导自适应近距离放疗可作为保留疾病控制和治疗安全的务实策略。
- 优先采用MRI引导、施源器在位的计划方式可能提高局部控制。
- 应关注总治疗时间,较短OTT与更高局部控制率相关。
局限性
- 回顾性研究设计。
- 中位随访时间较短(20.2个月)。
- 需要更长随访和扩大 accrual 以完善耐久性和预后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the feasibility, early outcomes, and toxicity of single-implant image-guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer in a multicenter French cohort; a pragmatic strategy to address limited and uneven access to utero-vaginal IGABT while preserving disease control and treatment safety. METHODS AND MATERIALS: We retrospectively analyzed 363 consecutive patients (Fédération Internationale de Gynécologie Obstétrique 2009 IB-IVA) treated with concurrent chemoradiation consisting of pelvic ± paraortic intensity modulated radiation therapy /volumetric modulated arc therapy (45 Gy in 25 fractions) with nodal boost to involved lymph nodes when indicated, followed by 1 applicator insertion delivering 4 high-dose-rate fractions. Planning was magnetic resonance imaging (MRI) guided with the applicator in place when available, otherwise computed tomography-guided with rigid fusion to an MRI performed a few days before. Composite doses were converted to equivalent doses per 2 Gy fractions, as per the linear-quadratic model. Outcomes (local control [LC], nodal and distant control, overall survival, and disease-free survival) were estimated by Kaplan-Meier from the end of radiation therapy. Late toxicity was graded according to the NCI-CTCAE version 5.0, with severe events defined as grade >= 3. RESULTS: T2b was the predominant T stage (59.5%), with nodal involvement in 47.9% of patients. The median overall treatment time (OTT) was 56 days (interquartile range, 50-61). Median D90-CTVHR (minimum dose delivered to 90% of the high-risk clinical target volume) was 85.9 GyEQD2 (IQR, 80.4-91.6 GyEQD2). At a median follow-up of 20.2 months (range, 1.6-121 months), the Kaplan-Meier-estimated 3-year LC rate was 83.1% (95% CI, 76.4-88.0). At 36 months, LC was higher with MRI-centered than computed tomography-MRI fusion planning (93.5% [85.7-97.2] vs 78.5% [70.4-84.6]) on unadjusted Kaplan-Meier. LC rates were 94% for patients with an OTT <50 days, 89% for those with an OTT of 50 to 55 days, and 81% for patients with an OTT >55 days. Overall, grade ≥3 toxicity events occurred in 14.0% of the cohort. CONCLUSIONS: In this multicenter real-world cohort, LC was high overall, particularly among patients treated with MRI-centered, applicator-in-place brachytherapy planning. Single-implant high-dose-rate IGABT for locally advanced cervical cancer was feasible, providing outcomes broadly consistent with historical multi-insertion series in terms of side effects. Longer follow-up and expanded accrual will refine durability and prognostic analyses.
引用
- Houdou L, Bruand M, Laroze S, et al. UNICURE-HD: A Multicentric Retrospective Cohort Study of Single-Insertion Image-Guided high-Dose-Rate Brachytherapy for Locally Advanced Cervical Cancer in the Context of Limited Brachytherapy Access in France. Int J Radiat Oncol Biol Phys. 2026. PMID: 42009109. doi:10.1016/j.ijrobp.2026.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。